Kaneka Eurogentec announced that the site expansion in Belgium would allow the GMP production of kg-scale plasmid DNA and recombinant protein intended for clinical phases and commercialization.
Seraing/Belgium — Kaneka Eurogentec announced that it will construct a new state of-the-art GMP facility adjacent to its current facility and equipped with a 2,200 liter fermenter.
The multi-product facility will include the capability for large scale production using the company's own technologies such as the production of complex proteins by secretion from yeasts and the production of kilo-scale plasmid DNA for viral and non-viral gene and cell therapies.
This expansion will be complementary to the current capabilities and together will provide small and industrial scale production.
Construction is expected to start in autumn of 2017. The expansion will result in the hiring of 40 full time scientific staff trained in the production of GMP therapeutic products.